Type II anti-CD20 antibody obinutuzumab outperforms rituximab in lupus trials, review finds
A new comparative review finds that the type II anti-CD20 antibody obinutuzumab succeeded in Phase 3 lupus trials where rituximab ...
A new comparative review finds that the type II anti-CD20 antibody obinutuzumab succeeded in Phase 3 lupus trials where rituximab ...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine